glp-1 and gip/glp-1 receptor agonists Dual agonists: New advances for treating type-2 diabetes glp 1 and gip glp

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.

Globally, 90% of diabetes patients have TIIDM

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron

Jardiance (empagliflozin) 38% CV death reduction vs Mounjaro (tirzepatide) 21% weight loss (EMPA-REG vs SURPASS)

Clinically backed oral GLP-1 support with a 321% natural GLP-1 boost

Curious about microdosing GLP-1s